Gena Wang
Stock Analyst at Barclays
(2.26)
# 2,661
Out of 4,893 analysts
203
Total ratings
40.3%
Success rate
-2.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $51 → $57 | $42.38 | +34.50% | 10 | Jul 1, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $89 → $29 | $19.07 | +52.11% | 10 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $57 → $59 | $31.47 | +87.48% | 3 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $5.42 | +84.50% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.50 | +900.00% | 4 | May 14, 2025 | |
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.65 | +142.42% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $59.00 | -28.81% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $4.35 | +773.56% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $49.51 | -15.17% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $36.59 | +44.85% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $8.88 | +23.87% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $31 → $25 | $22.03 | +13.48% | 9 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $40 | $34.28 | +16.69% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.93 | +422.77% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $12.16 | +113.82% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $479.53 | -2.61% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.06 | -1.96% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $4.48 | -10.71% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $322.58 | +1.99% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $58.82 | +46.21% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $9.06 | +451.88% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $31.04 | +161.00% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $39.71 | +136.72% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $13.67 | -34.14% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $14.48 | +72.65% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.62 | +108.82% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.53 | +155.32% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.85 | +4,600.85% | 1 | Jan 6, 2017 |
Ionis Pharmaceuticals
Jul 1, 2025
Upgrades: Overweight
Price Target: $51 → $57
Current: $42.38
Upside: +34.50%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $89 → $29
Current: $19.07
Upside: +52.11%
Avidity Biosciences
Jun 10, 2025
Maintains: Overweight
Price Target: $57 → $59
Current: $31.47
Upside: +87.48%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.42
Upside: +84.50%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.50
Upside: +900.00%
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.65
Upside: +142.42%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $59.00
Upside: -28.81%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $4.35
Upside: +773.56%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $49.51
Upside: -15.17%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $36.59
Upside: +44.85%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.88
Upside: +23.87%
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $22.03
Upside: +13.48%
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $34.28
Upside: +16.69%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.93
Upside: +422.77%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $12.16
Upside: +113.82%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $479.53
Upside: -2.61%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.06
Upside: -1.96%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $4.48
Upside: -10.71%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $322.58
Upside: +1.99%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $58.82
Upside: +46.21%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $9.06
Upside: +451.88%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $31.04
Upside: +161.00%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $39.71
Upside: +136.72%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.67
Upside: -34.14%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $14.48
Upside: +72.65%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.62
Upside: +108.82%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.53
Upside: +155.32%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.85
Upside: +4,600.85%